NCT05353361View on ClinicalTrials.gov

A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

402

Participants

Timeline

Start Date

May 23, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Breast Cancer
Interventions
DRUG

SHR-A1811：Pyrotinib

SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pyrotinib：Tablet, 160mg / tablet, 80mg / tablet, oral

DRUG

SHR-A1811；Pertuzumab

SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pertuzumab：Injection, 420 Mg (14 ml) / bottle, intravenous drip

DRUG

SHR-A1811；Adebrelimab

SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Adebrelimab：Injection, 12ml: 0.6g/bottle, intravenous drip

DRUG

SHR-A1811；Albumin paclitaxel

SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Albumin paclitaxel：Injection, 100mg / box, intravenous drip

Trial Locations (1)

210029

RECRUITING

Jiangsu Provincial People's Hospital, Nanjing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY